Plasma Chromogranin B as a Marker of Tumor Burden and Radiological Progression in Neuroendocrine Tumors Abstract #866

Introduction: Chromogranin-B (CgB) is expressed in most neuroendocrine tumors (NETs), yet little is understood about its clinical utility as a biomarker.
Aim(s): To investigate the role of CgB in follow-up of NET patients.
Materials and methods: Two-hundred and twelve patients [167 with midgut (mNETs), 45 pancreatic (pNETs)] with elevated plasma CgB levels were included. Correlations between CgB (normal <150pmol/L), tumor burden and histological grade, as well as its predictive value for radiological progression (RP), were investigated.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: David Braude

To read results and conclusion, please login ...

Further abstracts you may be interested in

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#12 Chromogranin A as a predictor of progression, regression or stable disease in ileo-cecal (midgut) carcinoid tumors
Introduction: A general characteristic for NETs is their expression of certain proteins, such as chromogranin A (CgA), which is released from the dense core vesicles of NE cells, occasionally together with cell specific hormones, such as gastrin and serotonin. Plasma CgA seems to be closely related to tumor burden of intestinal carcinoid tumors in humans.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kenneth Jensen
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan